Abnormal
angiogenesis is associated with diseases like proliferative diabetic
retinopathy (PDR)6 retinopathy of prematurity (ROP) and wet
(AMD).
‘The CRISPR-Cas9 system used for gene editing, depleted 80% of VEGFR2 in vitro and 30% in vivo.’
Diabetic retinopathy: In case of
diabetes, the tiny blood vessels (capillaries) in the back of the eye can
deteriorate and leak fluid into the retina. This causes the retina to swell,
which may blur vision. One may also develop new, abnormal capillaries that
break and bleed.
Macular
degeneration: In macular degeneration, the center of the retina begins to
deteriorate. This causes symptoms such as blurred central vision or a blind
spot in the center of the visual field. There are two types — wet macular
degeneration and dry macular degeneration.
Current
treatment
While there
are anti-VEGFR like
ranibizumab and
aflibercept can reduce neo-vascular
growth and vascular leakage, these approaches require chronic treatment. Also, a significant number of
patients do not respond to the treatment. Scientists believe that targeting
VEGFR2 locus using AAV-CRIPSR/Cas9 may provide a novel alternative approach.
Gene editing
approach
Adeno-associated
virus (AAV) mediated CRISPR-Cas9 was used to target the VEGFR2 locus. AAVs are
small viruses that are not known to cause any disease. Their vectors show
promise for human gene therapy.
The in-vitro analysis showed that the recombinant AAV
enabled transduction to pathological vessels of mouse primary brain
microvascular ECs (MVECs). 80%
of VEGFR2 expressio as depleted in this case. For in-vivo analysis, eye
diseases characterized by angiogenesis were simulated in mouse models. AAV-mediated
CRISPR-Cas9 edited VEGFR2 showed inhibition of angiogenesis
in two mouse models of oxygen-induced retinopathy and laser-induced choroid neo-vascular growth. 30% of VEGFR2
expression was depleted in-vivo.
The team believes that this approach forms a strong
foundation for treating other angiogenesis associated diseases.Concluding with
the words of the corresponding author, Dr. Lei said "While further study is
needed to determine safety and efficacy of this approach, our work shows that
the CRISPR-Cas9 system is a precise and efficient tool with the potential to
treat angiogenesis-associated diseases."
References :- Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., . . . Lei, H. (2017). Genome editing abrogates angiogenesis in vivo. Nature Communications, 8(1). doi:10.1038/s41467-017-00140-3
- Overview - Retinal Diseases - (http://www.mayoclinic.org/diseases-conditions/retinal-diseases/home/ovc-20312856)
Source: Medindia